BR0214902A - Preparação bacteriana, frações de preparação bacteriana, composição farmacêutica, uso da preparação bacteriana ou suas frações, método para a produção da preparação de bactérias mortas liofilizadas estendidas, kit para o tratamento de uma doença compreendendo uma desregulação imune, e, produtos - Google Patents

Preparação bacteriana, frações de preparação bacteriana, composição farmacêutica, uso da preparação bacteriana ou suas frações, método para a produção da preparação de bactérias mortas liofilizadas estendidas, kit para o tratamento de uma doença compreendendo uma desregulação imune, e, produtos

Info

Publication number
BR0214902A
BR0214902A BR0214902-8A BR0214902A BR0214902A BR 0214902 A BR0214902 A BR 0214902A BR 0214902 A BR0214902 A BR 0214902A BR 0214902 A BR0214902 A BR 0214902A
Authority
BR
Brazil
Prior art keywords
preparation
fractions
bacterial preparation
bacterial
kit
Prior art date
Application number
BR0214902-8A
Other languages
English (en)
Inventor
Marie-Anne Nahori
Micheline Lagranderie
Gilles Marchal
Bernardo Boris Vargaftig
Jean Lefort
Felix Romain
Georges Hekimian
Philippe Peltre
Original Assignee
Pasteur Institut
Inst Nat Sante Et La Rech Medi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Inst Nat Sante Et La Rech Medi filed Critical Pasteur Institut
Publication of BR0214902A publication Critical patent/BR0214902A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurology (AREA)

Abstract

"PREPARAçãO BACTERIANA, FRAçõES DE PREPARAçãO BACTERIANA, COMPOSIçãO FARMACêUTICA, USO DA PREPARAçãO BACTERIANA OU SUAS FRAçõES, MéTODO PARA A PRODUçãO DA PREPARAçãO DE BACTéRIAS MORTAS LIOFILIZADAS ESTENDIDAS, KIT PARA O TRATAMENTO DE UMA DOENçA COMPREENDENDO UMA DESREGULAçãO IMUNE, E, PRODUTOS". Composições compreendendo componentes preparados de bactérias Gram positivas, tais como bactérias intracelulares facultativas Gram positivas, por exemplo, micobactérias, incluindo bactérias Gram positivas mortas com liofilização estendida, seu método de preparação e seu uso em humanos e animais, para a prevenção e/ou tratamento de distúrbios compreendendo uma desregulação imune, tal como câncer, doenças autoimunes, alergia e tuberculose.
BR0214902-8A 2001-12-11 2002-12-11 Preparação bacteriana, frações de preparação bacteriana, composição farmacêutica, uso da preparação bacteriana ou suas frações, método para a produção da preparação de bactérias mortas liofilizadas estendidas, kit para o tratamento de uma doença compreendendo uma desregulação imune, e, produtos BR0214902A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01403195 2001-12-11
PCT/IB2002/005760 WO2003049752A2 (en) 2001-12-11 2002-12-11 Gram positive bacteria preparations for the treatment of diseases comprising an immune dysregulation

Publications (1)

Publication Number Publication Date
BR0214902A true BR0214902A (pt) 2004-11-30

Family

ID=8183013

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0214902-8A BR0214902A (pt) 2001-12-11 2002-12-11 Preparação bacteriana, frações de preparação bacteriana, composição farmacêutica, uso da preparação bacteriana ou suas frações, método para a produção da preparação de bactérias mortas liofilizadas estendidas, kit para o tratamento de uma doença compreendendo uma desregulação imune, e, produtos

Country Status (17)

Country Link
US (3) US20060062807A1 (pt)
EP (2) EP1461054B1 (pt)
JP (2) JP4737586B2 (pt)
KR (2) KR101048798B1 (pt)
CN (1) CN1602199B (pt)
AT (1) ATE466585T1 (pt)
AU (1) AU2002356387C1 (pt)
BR (1) BR0214902A (pt)
CA (1) CA2469334C (pt)
CY (1) CY1110727T1 (pt)
DE (1) DE60236318D1 (pt)
DK (2) DK1461054T3 (pt)
ES (1) ES2345188T3 (pt)
NZ (2) NZ533422A (pt)
PT (1) PT1461054E (pt)
SI (1) SI1461054T1 (pt)
WO (1) WO2003049752A2 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1461054E (pt) * 2001-12-11 2010-08-09 Pasteur Institut Preparações de bactérias gram positivas para o tratamento de doenças que implicam uma desregulação imunitária
AU2003263319B2 (en) * 2002-09-06 2009-07-02 University College London Whole bacterial cells as immune modulator
WO2005049056A2 (en) * 2003-11-14 2005-06-02 Ucl Biomedica Plc Immune modulator comprising whole cell rhodococcus, gordonia, nocardia, dietzia, tsukamurella or nocardioides bacteria
US7892557B2 (en) 2004-02-19 2011-02-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Peptide mimotopes of mycobacterial mannosylated lipoglycans and uses thereof
US8501198B2 (en) 2004-06-07 2013-08-06 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
NZ581806A (en) * 2004-06-07 2011-10-28 Qu Biolog Inc Bacterial compositions for the treatment of cancer
US9107864B2 (en) 2004-06-07 2015-08-18 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
US8034359B2 (en) 2004-06-07 2011-10-11 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to cancers
DE602005017391D1 (de) 2004-06-24 2009-12-10 Yissum Res Dev Co Verwendung von peptid-mimotopen von mannosylierten lipoglycanen aus mycobacterien zur behandlung von entzündungen
CA2531261A1 (en) * 2005-12-21 2007-06-21 Institut Pasteur Control of intestinal inflammatory syndromes with a preparation of killed or non infectious bacteria
NZ576590A (en) * 2006-10-27 2012-08-31 Qu Biolog Inc Tissue targeted antigenic activation of the immune response to treat cancers
GB0716778D0 (en) * 2007-08-29 2007-10-10 Bioeos Ltd Use
EP2087898A1 (en) * 2008-02-06 2009-08-12 Institut Pasteur A preparation of mycobacterium bovis BCG killed by extended freeze drying (EFD) for treating rheumatoid arthritis
CA2629057A1 (en) * 2008-04-14 2009-10-14 Institut Pasteur Control of diseases associated with decrease of t-regulatory cells with a preparation of extended freeze-dried killed bacteria
HUP0900231A2 (hu) * 2009-04-16 2010-11-29 Hyd Rakkutato Es Gyogyszerfejlesztoe Kft Allergiás betegségek kezelésére, gyógyítására alkalmas készítmények és eljárás azok elõállítására
EP2292260A1 (en) 2009-08-13 2011-03-09 Institut Pasteur Use of mycobacterium bovis BCG killed by extended freeze drying (EFD) for preventing or treating atherosclerosis
EP2620159A1 (en) 2012-01-24 2013-07-31 Institut Pasteur Improved cancer treatment by immunotherapy with bcg or antigenically related non-pathogenic mycobacteria
CA2947631A1 (en) 2014-05-02 2015-11-05 Qu Biologics Inc. Anti-microbial immunomodulation
WO2017143386A1 (en) * 2016-02-25 2017-08-31 Borody Thomas J Compositions and methods of treatment of chronic infectious diseases
JP2022505421A (ja) * 2018-10-17 2022-01-14 サイバック インコーポレーテッド 肺疾病を処置および予防するための生きた生物学的製剤
WO2020115161A1 (en) 2018-12-04 2020-06-11 Sabiotec Spin-Off Sl Immunostimulant for use against pathogens
US20220047648A1 (en) * 2019-01-09 2022-02-17 Md Healthcare Inc. Nanovesicles derived from bacteria of genus rhodococcus, and use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2594471A (en) * 1946-10-11 1952-04-29 Comb Eng Superheater Inc Heat exchange apparatus
GB764718A (en) * 1954-08-10 1957-01-02 Glaxo Lab Ltd Improvements in or relating to freeze-drying processes
GB1027979A (en) * 1963-07-12 1966-05-04 Ciba Ltd Process for obtaining bcg-cultures
GB1163470A (en) * 1967-11-13 1969-09-04 Cecil Arthur Clark Improvements in or relating to Adjuvant Vaccines
JPS57186495A (en) 1981-05-14 1982-11-16 Ube Ind Ltd Preparation of l-alpha-methylphenylalanine
GB8404280D0 (en) 1984-02-17 1984-03-21 Stanford J L Biological preparations
IN164864B (pt) 1985-05-13 1989-06-24 Commw Scient Ind Res Org
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
JPS63126830A (ja) * 1986-11-17 1988-05-30 Isao Moriya 動植物の体内に抗体を生成する方法
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
GB9801870D0 (en) * 1998-01-28 1998-03-25 Raby Limited Vaccine composition
SE9900495D0 (sv) * 1999-02-12 1999-02-12 Pharmatrix Ab Vaccine composition
US6350457B1 (en) 1999-06-02 2002-02-26 Genesis Research & Development Corporation Limited Methods and compounds for the treatment of immunologically-mediated diseases using mycobacterium vaccae
PT1461054E (pt) 2001-12-11 2010-08-09 Pasteur Institut Preparações de bactérias gram positivas para o tratamento de doenças que implicam uma desregulação imunitária

Also Published As

Publication number Publication date
KR20110028558A (ko) 2011-03-18
PT1461054E (pt) 2010-08-09
EP2316466A2 (en) 2011-05-04
EP1461054A2 (en) 2004-09-29
NZ533422A (en) 2008-03-28
JP2005516915A (ja) 2005-06-09
CA2469334A1 (en) 2003-06-19
US20060062807A1 (en) 2006-03-23
JP2011121977A (ja) 2011-06-23
ES2345188T3 (es) 2010-09-17
EP1461054B1 (en) 2010-05-05
EP2316466A3 (en) 2012-04-11
JP4737586B2 (ja) 2011-08-03
US7871627B2 (en) 2011-01-18
NZ555055A (en) 2010-06-25
AU2002356387C1 (en) 2008-03-06
ATE466585T1 (de) 2010-05-15
AU2002356387B2 (en) 2007-09-13
KR101124363B1 (ko) 2012-03-21
WO2003049752A3 (en) 2003-11-20
KR101048798B1 (ko) 2011-07-15
KR20040080434A (ko) 2004-09-18
US8404250B2 (en) 2013-03-26
DK2316466T3 (da) 2013-11-18
WO2003049752A2 (en) 2003-06-19
CY1110727T1 (el) 2015-06-10
CA2469334C (en) 2012-05-08
CN1602199A (zh) 2005-03-30
CN1602199B (zh) 2012-04-04
AU2002356387A1 (en) 2003-06-23
US20070190076A1 (en) 2007-08-16
EP2316466B1 (en) 2013-08-21
JP5417354B2 (ja) 2014-02-12
DE60236318D1 (de) 2010-06-17
HK1067073A1 (en) 2005-04-01
US20100272756A1 (en) 2010-10-28
SI1461054T1 (sl) 2010-09-30
DK1461054T3 (da) 2010-08-16

Similar Documents

Publication Publication Date Title
BR0214902A (pt) Preparação bacteriana, frações de preparação bacteriana, composição farmacêutica, uso da preparação bacteriana ou suas frações, método para a produção da preparação de bactérias mortas liofilizadas estendidas, kit para o tratamento de uma doença compreendendo uma desregulação imune, e, produtos
BR0214962A (pt) Composição para tratar distúrbios neurocerebrovasculares
ATE375164T1 (de) Endotoxin-bindung durch milchsäurebakterien und bifidobacteria
BR0214705A (pt) Composição, seu uso, método para prevenção ou tratamento de doença neurodegenerativa, e kit
TW200507874A (en) Immunostimulatory nucleic acid oil-in-water formulations and related methods of use
WO2002094228A8 (en) Prevention and treatment of allergies by helminthic regulation of ige
ITMI20020399A1 (it) Composizioni dietetiche e/o farmaceutiche per uso umano e/o animale abase di preparati microbici probiotici
DOP2002000429A (es) Imidazotriazinas
BRPI0407662B8 (pt) derivados do ácido 1-fenilalcanocarboxílico para o tratamento de doenças neurodegenerativas
WO2003099771A3 (en) Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
DE69929232D1 (de) Virusähnliche partikel zur induktion von autoantikörpern
MXPA06000660A (es) Uso de una composicion cosmetica o farmaceutica que comprende un extracto rico en lupeol, como un ingrediente activo para estimular la sintesis de proteinas de choque termico.
BR0314511A (pt) Seleção e uso de bactérias de ácido lático para reduzir a inflamação causada por helicobater
WO2005020928A3 (en) Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins
BR0015698A (pt) Composições e métodos para tratamento de doenças alérgicas
DE60106026D1 (de) 2-arachidonylglycerol, ein hemmer des tumor nekrose faktors -alfa und neuroprotektor des gehirns bei geschlossenen kopfverletzungen
NO20010940D0 (no) TAN-1057 derivater
WO2003024996A3 (de) Antibakterielle makrozyklen
DE60235418D1 (de) Osteoprotegerin in Milch
AR045745A1 (es) Fracciones de leche y preparaciones de leche para el tratamiento y/o prevencion de las enfermedades mediadas por cox-2
NO20051159L (no) Preparater og fremgangsmater for behandling av sykdommer som viser feilsammensetting av aggregering av protein
EP1498145A4 (en) LURE FOR THE TREATMENT AND / OR PREVENTION OF ALLERGIC DISEASE ASSOCIATED WITH CYTOKINE TH2, MUTANT PROTEIN GATA3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME
WO2003053959A8 (de) Heterocyclylaminocarbo nyluracile
WO2006129090A3 (en) Vaccines
BR0314109A (pt) Dibenzoxazepinas

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.